source
- Eli Lilly’s $3.8 billion acquisition of AtaiBeckley signals strong backing for psychedelic therapeuticsNovartis and Roche kicked off the second‑quarter earnings season, with other majors such as AstraZeneca, GSK and Biogen slated to follow. The earnings wave highlights continued revenue growth acros…
- Arrowhead reports Phase 3 data showing potentially best-in-class triglyceride reduction, eyes FDA filingArrowhead Pharmaceuticals announced topline results from two late-stage Phase 3 trials (SHASTA-3 and SHASTA-4) of its siRNA drug plozasiran in patients with severe hypertriglyceridemia (sHTG). Th…